Market Overview:
The global treatment for communicable diseases market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of communicable diseases, growing awareness about available treatments, and the increasing demand for novel therapies. The global treatment for communicable diseases market is segmented by type into HIV, influenza, tuberculosis (TB), malaria, hepatitis, and HPV. The HIV segment is expected to account for the largest share of the global market in 2018. This segment is projected to grow at a CAGR of 8% from 2018 to 2030 due to the increasing incidence of HIV/AIDS across the globe. The hepatitis segment is projected to grow at a CAGR of 9% from 2018to 2030 due its high prevalence rate and lack of effective treatments currently available in the market.
Product Definition:
Treatment for communicable diseases is the use of medication and other methods to cure or prevent the spread of a communicable disease. Treatment for communicable diseases is important because it can help prevent the spread of disease and help people recover from an illness.
HIV:
HIV is the virus that causes aids. It is transmitted through blood and other body fluids of an infected person. There are five different classifications of HIV: Group O, Group M, Group N, Chain B and Multi-drug Resistant (MDR). The most common form in which it appears at present is group O.
Influenza:
Influenza is an infectious disease of the upper respiratory system caused by the influenza virus. The flu is generally a contagious disease and can be transmitted from one person to another by cough, sneeze or transmit through air. Influenza (flu) viruses are found in animals and plants. There are many different types of influenza viruses which differ in their surface proteins ( neuraminidase)and genome segments.
Application Insights:
The hospital segment dominated the global treatment for communicable diseases market in 2017. This can be attributed to factors such as increasing healthcare spending, growing prevalence of chronic diseases and an increase in the number of patients requiring admission. According to WHO, around 30% of total healthcare expenditure goes towards communicable disease management which is expected to boost demand over the forecast period.
Furthermore, due to a rise in travelers from developed countries with high-quality health systems who are at risk of developing certain infectious diseases due to absence of immunity or prior infection, there has been an increased focus on controlling these infections by improving hygiene and sanitation conditions across hospitals globally. This is anticipated to further drive demand over the forecast period as various governments are taking initiatives against it by formulating policies and laws regarding it which will eventually result in increased spending on treatments resulting in higher revenue generation for this industry during 2018-2030 period.
Regional Analysis:
North America dominated the global market in 2017. The presence of sophisticated healthcare infrastructure, high awareness levels coupled with the availability of effective treatment forcommunicable diseases are some factors responsible for its large share. Moreover, increasing government initiatives to control these diseases is also expected to drive regional growth over the forecast period. For instance, according to CDC’s National Notifiable Diseases Surveillance System (NNDSS), from 2000-2016 an estimated 4,879 COVID-19 cases were reported in U.S.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising investments by governments.
Growth Factors:
- Increasing incidence of communicable diseases
- Growing awareness about the treatment for communicable diseases
- Rising demand for better and effective treatments for communicable diseases
- Technological advancements in the field of diagnostics and therapeutics for communicable diseases 5. Government initiatives to support research and development in the field of treatment for communicable diseases
Scope Of The Report
Report Attributes
Report Details
Report Title
Treatment for Communicable Diseases Market Research Report
By Type
HIV, Influenza, TB, Malaria, Hepatitis, HPV
By Application
Hospital, Clinic, Other
By Companies
Novartis, Gilead, GSK, Janssen Pharmaceutical, Roche, BioCryst Pharmaceuticals, Merck, Boehringer Ingelheim
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
138
Number of Tables & Figures
97
Customization Available
Yes, the report can be customized as per your need.
Global Treatment for Communicable Diseases Market Report Segments:
The global Treatment for Communicable Diseases market is segmented on the basis of:
Types
HIV, Influenza, TB, Malaria, Hepatitis, HPV
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Gilead
- GSK
- Janssen Pharmaceutical
- Roche
- BioCryst Pharmaceuticals
- Merck
- Boehringer Ingelheim
Highlights of The Treatment for Communicable Diseases Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- HIV
- Influenza
- TB
- Malaria
- Hepatitis
- HPV
- By Application:
- Hospital
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Treatment for Communicable Diseases Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one-size-fits-all answer to this question, as the best treatment for a communicable disease will vary depending on the specific condition and individual. However, some general treatments that may be used to treat communicable diseases include antibiotics, antiviral medications, and other medical treatments.
Some of the major players in the treatment for communicable diseases market are Novartis, Gilead, GSK, Janssen Pharmaceutical, Roche, BioCryst Pharmaceuticals, Merck, Boehringer Ingelheim.
The treatment for communicable diseases market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Treatment for Communicable Diseases Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Treatment for Communicable Diseases Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Treatment for Communicable Diseases Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Treatment for Communicable Diseases Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Treatment for Communicable Diseases Market Size & Forecast, 2020-2028
4.5.1 Treatment for Communicable Diseases Market Size and Y-o-Y Growth
4.5.2 Treatment for Communicable Diseases Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 HIV
5.2.2 Influenza
5.2.3 TB
5.2.4 Malaria
5.2.5 Hepatitis
5.2.6 HPV
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Treatment for Communicable Diseases Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Treatment for Communicable Diseases Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 HIV
9.6.2 Influenza
9.6.3 TB
9.6.4 Malaria
9.6.5 Hepatitis
9.6.6 HPV
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 HIV
10.6.2 Influenza
10.6.3 TB
10.6.4 Malaria
10.6.5 Hepatitis
10.6.6 HPV
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 HIV
11.6.2 Influenza
11.6.3 TB
11.6.4 Malaria
11.6.5 Hepatitis
11.6.6 HPV
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 HIV
12.6.2 Influenza
12.6.3 TB
12.6.4 Malaria
12.6.5 Hepatitis
12.6.6 HPV
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 HIV
13.6.2 Influenza
13.6.3 TB
13.6.4 Malaria
13.6.5 Hepatitis
13.6.6 HPV
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Treatment for Communicable Diseases Market: Competitive Dashboard
14.2 Global Treatment for Communicable Diseases Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Gilead
14.3.3 GSK
14.3.4 Janssen Pharmaceutical
14.3.5 Roche
14.3.6 BioCryst Pharmaceuticals
14.3.7 Merck
14.3.8 Boehringer Ingelheim
